Clinical Trial Detail

NCT ID NCT04034927
Title Testing the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer
Recruitment Recruiting
Gender female
Phase Phase II
Variant Requirements No
Sponsors National Cancer Institute (NCI)

ovarian clear cell carcinoma

ovarian serous carcinoma

mixed epithelial tumor of ovary

endometrioid ovary carcinoma

ovary transitional cell carcinoma

peritoneum cancer

fallopian tube cancer



Olaparib + Tremelimumab

Age Groups: adult senior

No variant requirements are available.